The latest leukaemia news
Long term benefits for chronic lymphocytic leukaemia patients
Chronic lymphocytic leukaemia (CLL) patients who are refractory or resistant to treatment can be encouraged…
Browsing: Leukaemia
‘Goldilocks’ treatment window could lead to cancer therapy without harmful side-effects
Researchers have developed a way to potentially reduce the toxic side-effects of a type of…
New effective combination therapy for paediatric T-acute leukaemia
Acute lymphoblastic leukaemia (ALL) is the most common cancer affecting children. The T-ALL form of…
Joining forces with nature for new cancer therapies
Natural compounds often have promising therapeutic potential but their use to treat diseases is hampered…
New effective combination therapy for paediatric T-acute leukaemia
Acute lymphoblastic leukaemia (ALL) is the most common cancer affecting children. The T-ALL form of…
EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with venetoclax in fit patients with treatment-naïve chronic lymphocytic leukaemia
Chemoimmunotherapy (CIT) is still standard treatment for patients with chronic lymphocytic leukaemia (CLL), particularly when…
EHA 2022: Quizartinib improves overall survival in adults with FLT3-ITD+ acute myeloid leukaemia
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, and approximately 25%…
EHA 2022: Decitabine shows similar survival and fewer adverse events compared to standard chemo in geriatric AML
Acute myeloid leukaemia (AML) predominantly occurs in older adults over 65 years, who exhibit a…
EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations
Mutations in SF3B1 and U2AF1 can drive overexpression of activated IRAK4 — which regulates inflammation and promotes cancer cell…
EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant AML
High-risk patients with TP53-mutated acute myeloid leukaemia (AML) have limited treatment options and very poor prognoses.…